{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T02:32:26Z","timestamp":1787884346064,"version":"build-2784847793"},"reference-count":17,"publisher":"Bioscientifica","issue":"7","content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Plurihormonal pituitary neuroendocrine tumors\/pituitary adenomas (PitNET\/PAs) express multiple hormones and\/or transcription factors. The two most common subtypes within the plurihormonal category are immature PIT-1 (pituitary-specific POU-class homeodomain factor-1) lineage tumors and mature PIT-1 plurihormonal tumors, most of which show PIT-1\/SF-1 (steroidogenic factor 1) co-expression. Our aim is to provide direct comparison between these two PIT-1 plurihormonal tumor types in terms of demographic, radiological, neurosurgical, and endocrinological features. A database search and chart review of patients with plurihormonal PitNET\/PAs who underwent resection between 2018 and 2024 was performed. Twenty-six plurihormonal PitNET\/PAs (12 immature PIT-1-lineage and 14 mature PIT-1\/SF-1 co-expressors) were identified. Immature PIT-1 lineage tumors were larger than mature PIT-1\/SF-1 co-expressors (median size 27.5 vs 16 mm, P = 0.02). No significant differences were detected between the two groups in terms of gender (females 67 vs 50%), median age (45 vs 50 years), hormonal activity (83 vs 79%), invasion of the cavernous sinuses (50% each), residual tumor after surgery (55 vs 43%) or rate of recurrence (9 vs 7%). Immature PIT-1 lineage tumors trended toward higher Ki-67 levels when compared to mature PIT-1\/SF-1 co-expressors (30 vs 0%, P = 0.21) and need for medical therapy after surgery for hormone excess (33 vs 7%, P = 0.15), but this was not statistically significant. In conclusion, immature PIT-1 lineage tumors exhibit larger size and an increased requirement for postoperative medical therapy than mature PIT-1\/SF-1 co-expressors, underscoring the usefulness of careful histological analysis. In contrast, these two plurihormonal subtypes cannot be predicted pre-operatively by gender, age, or hormonal profile.<\/jats:p>","DOI":"10.1530\/erc-25-0020","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T09:56:18Z","timestamp":1751622978000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":3,"title":["Clinical features of plurihormonal pituitary adenoma subtypes"],"prefix":"10.1530","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1336-7149","authenticated-orcid":true,"given":"Christie G","family":"Turin","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado School of Medicine 1 , , ,","place":["Aurora, Colorado, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Kiseljak-Vassiliades","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado School of Medicine 1 , , ,","place":["Aurora, Colorado, USA"]},{"name":"Section of Endocrinology, Department of Medicine, Research Service at Rocky Mountain Regional Veterans Affairs Medical Center, 2 , ,","place":["Aurora, Colorado, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret E","family":"Wierman","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado School of Medicine 1 , , ,","place":["Aurora, Colorado, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Lillehei","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University of Colorado School of Medicine 3 , , ,","place":["Aurora, Colorado, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B K","family":"Kleinschmidt-DeMasters","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University of Colorado School of Medicine 3 , , ,","place":["Aurora, Colorado, USA"]},{"name":"Department of Pathology, University of Colorado School of Medicine 4 , , ,","place":["Aurora, Colorado, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2025,7,4]]},"reference":[{"key":"2026070905430552900_bib1","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1016\/j.wneu.2021.04.003","article-title":"Plurihormonal PIT-1-positive pituitary adenomas: a systematic review and single-center series","volume":"151","author":"Andrews","year":"2021","journal-title":"World Neurosurg"},{"key":"2026070905430552900_bib2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s12022-022-09703-7","article-title":"Overview of the 2022 WHO classification of pituitary tumors","volume":"33","author":"Asa","year":"2022","journal-title":"Endocr Pathol"},{"key":"2026070905430552900_bib4","volume-title":"WHO Classification of Tumours, Endocrine and Neuroendocrine Tumours","author":"Asa","year":"2022","edition":"5th edition"},{"key":"2026070905430552900_bib3","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s12022-023-09777-x","article-title":"Multilineage pituitary neuroendocrine tumors (PitNETs) expressing PIT1 and SF1","volume":"34","author":"Asa","year":"2023","journal-title":"Endocr Pathol"},{"key":"2026070905430552900_bib5","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1089\/thy.2016.0046","article-title":"Spine stereotactic radiosurgery for patients with metastatic thyroid cancer: secondary analysis of phase I\/II trials","volume":"26","author":"Bernstein","year":"2016","journal-title":"Thyroid"},{"key":"2026070905430552900_bib6","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1210\/clinem\/dgad098","article-title":"Aggressive pituitary tumors and pituitary carcinomas: from pathology to treatment","volume":"108","author":"Burman","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905430552900_bib7","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s11154-020-09556-7","article-title":"The epidemiology of aggressive pituitary tumors (and its challenges)","volume":"21","author":"Dekkers","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"key":"2026070905430552900_bib8","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s00401-024-02686-1","article-title":"Pituitary neuroendocrine tumors with PIT1\/SF1 co-expression show distinct clinicopathological and molecular features","volume":"147","author":"Dottermusch","year":"2024","journal-title":"Acta Neuropathol"},{"key":"2026070905430552900_bib9","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s11060-014-1413-6","article-title":"Management of aggressive pituitary adenomas and pituitary carcinomas","volume":"117","author":"Heaney","year":"2014","journal-title":"J Neuro Oncol"},{"key":"2026070905430552900_bib10","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1097\/PAS.0000000000002306","article-title":"Reassessment of plurihormonal pituitary adenomas\/PitNETs","volume":"48","author":"Kleinschmidt-DeMasters","year":"2024","journal-title":"Am J Surg Pathol"},{"key":"2026070905430552900_bib11","volume-title":"WHO Classification of Tumours, Central Nervous System Tumours","author":"Lopes","year":"2021","edition":"5th edition"},{"key":"2026070905430552900_bib12","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/modpathol.2015.151","article-title":"Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas","volume":"29","author":"Mete","year":"2016","journal-title":"Mod Pathol"},{"key":"2026070905430552900_bib13","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ccell.2019.11.002","article-title":"Pangenomic classification of pituitary neuroendocrine tumors","volume":"37","author":"Neou","year":"2020","journal-title":"Cancer Cell"},{"key":"2026070905430552900_bib14","doi-asserted-by":"crossref","first-page":"iii1","DOI":"10.1093\/neuonc\/noab200","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014\u20132018","volume":"23","author":"Ostrom","year":"2021","journal-title":"Neuro Oncol"},{"key":"2026070905430552900_bib15","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-17-0796","article-title":"European society of endocrinology clinical practice guidelines for the management of aggressive pituitary tumours and carcinomas","volume":"178","author":"Raverot","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"2026070905430552900_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fsurg.2022.826720","article-title":"Clinicopathological characteristics of plurihormonal pituitary adenoma","volume":"9","author":"Shi","year":"2022","journal-title":"Front Surg"},{"key":"2026070905430552900_bib17","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1227\/neu.0000000000002846","article-title":"Clinical and pathological features of Pit1\/SF1 multilineage pituitary neuroendocrine tumor","volume":"95","author":"Wang","year":"2024","journal-title":"Neurosurgery"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/32\/7\/ERC-25-0020.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/32\/7\/ERC-25-0020.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-25-0020\/145023\/erc-25-0020.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-25-0020\/145023\/erc-25-0020.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T09:43:14Z","timestamp":1783590194000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article\/32\/7\/e250020\/25916\/Clinical-features-of-plurihormonal-pituitary"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.1530\/erc-25-0020","relation":{},"ISSN":["1479-6821","1351-0088"],"issn-type":[{"value":"1479-6821","type":"electronic"},{"value":"1351-0088","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"article-number":"e250020"}}